Ligand Pharmaceuticals

-

Stock Issuer and Owners

Home | Sign Up | Log In
List of Funds
Boston Firms
Boston Hedge Funds
Cornell Alumni Firms
CalPERS Portfolio
NYSCRF Portfolio
Latest Filings
User Guide
Regulatory AUM vs AUM
LP Portfolios
Related Firms
Build a Portfolio
Comprehensive Search
Ligand Pharmaceuticals
TickerLGND
CIK #0000886163
CUSIP53220K504
SectorLife Sciences
IndustryPharmaceutical Preparations
Phone8585507500
Address11085 North Torrey Pines Road Suite 300
La Jolla, CA 92037
Source [EDGAR]
Market Cap, 13F ($BB)
4.03.22.41.60.80.02011201320152018
Business

We are a biopharmaceutical company focused on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. We employ research technologies such as antibody discovery technologies, structure-based drug design, formulation science and liver targeted pro-drug technologies to assist companies in their work toward securing prescription drug and biologic approvals. We currently have partnerships and license agreements with over 120 pharmaceutical and biotechnology companies. Over 200 different programs are in various stages of commercialization and development and fully funded by our collaboration partners and licensees. We have contributed novel research and technologies for approved medicines that treat cancer, osteoporosis, fungal infections and PPD, among others. Our collaboration partners and licensees have programs currently in clinical development targeting cancer, seizure, diabetes, cardiovascular disease, muscle wasting, liver disease, and kidney disease, among others. We have over 1,200 issued patents worldwide.

We have assembled our large portfolio of fully-funded programs either by licensing our own proprietary drug development programs, licensing our platform technologies such as Captisol or OmniAb to partners for use with their proprietary programs, or acquiring existing partnered programs from other companies. Fully-funded programs, which we refer to as "shots on goal," are those for which our partners pay all of the development and commercialization costs. For our internal programs, we generally plan to advance drug candidates through early-stage drug development or clinical proof-of-concept and then seek partners to continue development and potential commercialization.

Our business model creates value for stockholders by providing a diversified portfolio of biotech and pharmaceutical product revenue streams that are supported by an efficient and low corporate cost structure. Our goal is to offer investors an opportunity to participate in the promise of the biotech industry in a profitable, diversified and lower-risk business than a typical biotech company. Our business model is based on doing what we do best: drug discovery, early-stage drug development, product reformulation and partnering. We partner with other pharmaceutical companies to leverage what they do best (late-stage development, regulatory management and commercialization) to ultimately generate our revenue. We believe that focusing on discovery and early-stage drug development while benefiting from our partners' development and commercialization expertise will reduce our internal expenses and allow us to have a larger number of drug candidates progress to later stages of drug development.

CIK Filing 2011 - 2021
[0000886163] 10-K
[0000886163] 10-Q
[0000886163] 3
[0000886163] 4
[0000886163] 5
[0000886163] 8-K
[0000886163] D
[0000886163] SC 13D
[0000886163] SC 13G
Form 13D/13G Filer Form 13D/13G Subject Filed % Owned
Bank of America Corp /DE/ Ligand Pharmaceuticals Inc [2020-02-14] 5.8
State Street Corp Ligand Pharmaceuticals Inc [2020-02-14] 7.14
Cardinal Capital Management LLC /CT Ligand Pharmaceuticals Inc [2020-02-14] 5.2
Janus Henderson Group PLC Ligand Pharmaceuticals Inc [2020-01-10] 10.5
Ligand Pharmaceuticals Inc Seelos Therapeutics Inc [2019-04-15] 9.99
Renaissance Technologies LLC Ligand Pharmaceuticals Inc [2019-02-12] 6.97
FMR LLC Ligand Pharmaceuticals Inc [2016-02-12] 0.0
William Blair Investment Management LLC Ligand Pharmaceuticals Inc [2016-02-09] 5.72
KCG Americas LLC Ligand Pharmaceuticals Inc [2016-02-03] 9.63
Ligand Pharmaceuticals Inc Viking Therapeutics Inc [2015-05-08] 49.8
Cardinal Capital Management LLC /CT Ligand Pharmaceuticals Inc [2015-02-12] 5.0
Vanguard Group Inc Ligand Pharmaceuticals Inc [2015-02-10] 5.07
RS Investment Management Co LLC Ligand Pharmaceuticals Inc [2014-02-14] 6.44
FMR LLC Ligand Pharmaceuticals Inc [2014-02-14] 0.0
Blair William & Co/Il Ligand Pharmaceuticals Inc [2014-02-06] 5.96
Vanguard Group Inc Ligand Pharmaceuticals Inc [2013-02-13] 5.32
Ligand Pharmaceuticals Inc Desert Gateway Inc [2013-01-11] 7.44
Park West Asset Management LLC Ligand Pharmaceuticals Inc [2012-12-26] 5.1
BlackRock Inc Ligand Pharmaceuticals Inc [2012-02-09] 6.01
Form 3/4/5 Filer 2011-2021
Higgins John L
Patel Sunil
Pfenex Inc
Viking Therapeutics Inc
Foehr Matthew W
Korenberg Matthew E
Berkman Charles S
Kozarich John W
Sabba Stephen L
Aryeh Jason
Boyce Sarah
Davis Todd C
Gray Nancy Ryan
Lamattina John L
Goldman Sachs Group Inc
Goldman Sachs & Co LLC
Herman Melanie J
Knott David M
Desilva Nishan M
BVF Partners L P/IL
Lampert Mark N
Biotechnology Value Fund II LP
Biotechnology Value Fund L P
BVF Inc/Il
BVF Investments LLC
Investment 10 LLC
Sharp John P
Kazmi Syed
MM Shares Owned of 21.3 MM Total
Firm Period DFND Voting Shares
BlackRock Inc. [2020-09-30] SOLE 2.1 2.1
William Blair Investment Management LLC [2020-09-30] SOLE 1.7 1.9
Janus Henderson Group PLC [2020-09-30] DFND 0.0 1.6
Vanguard Group Inc [2020-09-30] SOLE 0.0 1.4
Wasatch Advisors Inc [2020-09-30] SOLE 0.9 1.1
State Street Corp [2020-09-30] DFND 0.9 1.0
Cardinal Capital Management LLC /CT [2020-09-30] SOLE 0.7 0.9
Macquarie Group Ltd [2020-09-30] SOLE 0.8 0.8
Conestoga Capital Advisors LLC [2020-09-30] SOLE 0.7 0.7
Villere St Denis J & Co LLC [2020-09-30] SOLE 0.7 0.7
Melvin Capital Management LP [2020-09-30] SOLE 0.6 0.6
Stephens Investment Management Group LLC [2020-09-30] DFND 0.0 0.6
Chicago Capital LLC [2020-09-30] SOLE 0.5 0.5
Goldman Sachs Group Inc [2020-09-30] DFND 0.4 0.4
Kornitzer Capital Management Inc /KS [2020-09-30] SOLE 0.4 0.4
Rice Hall James & Associates LLC [2020-09-30] SOLE 0.3 0.4
Dimensional Fund Advisors LP [2020-09-30] DFND 0.4 0.4
Stonepine Capital Management LLC [2020-09-30] SOLE 0.3 0.3
Citadel Advisors LLC [2020-09-30] DFND 0.3 0.3
Northern Trust Corp [2020-09-30] DFND 0.0 0.3
Knott David M [2020-09-30] DFND 0.2 0.2
Eaton Vance Management [2020-09-30] SOLE 0.2 0.2
Geode Capital Management LLC [2020-09-30] DFND 0.2 0.2
Arrowstreet Capital Limited Partnership [2020-09-30] DFND 0.2 0.2
Bank of America Corp /DE/ [2020-09-30] DFND 0.0 0.2
Ameriprise Financial Inc [2020-09-30] DFND 0.0 0.2
Standard Life Aberdeen plc [2020-09-30] DFND 0.2 0.2
Invesco Ltd. [2020-09-30] DFND 0.0 0.2
Victory Capital Management Inc [2020-09-30] SOLE 0.2 0.2
Price T Rowe Associates Inc /MD/ [2020-09-30] SOLE 0.0 0.2
Prev | Page 1 | Next
Terms | Privacy | Guide
tony@aum13f.com